Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Chambal Fertiliser - Results better estimates, reiterate Buy - Phillip Capital

Posted On: 2013-02-02 03:05:24

Results better estimates, urea/trading surprise: Chambal's Q3 results bettered our estimates on the topline/Ebitda and PAT front by 10/4/5% resp - Urea division bettered our estimates on the topline/Ebit front.

Urea division revenues/Ebit topped our estimates and grew 26%/22% yoy to Rs 10.25 bn/1.4 bn. Ebit margins improved to Rs 2400/mt against Rs 2100/mt in H1FY13; largely led by external ammonia sales. Overall revenues improved 72% qoq to Rs 23.4 bn; however Ebitda improved only by 4% to Rs 1.94 bn (below estimates). The reported PAT is Rs 1095 mn and the adj PAT is Rs 994 mn below our estimates by 6%.

Revenues at Rs 20.87 bn, degrew 11% qoq (up 17% yoy) largely led by lower trading, understandably given weak demand. Ebitda at Rs 2.1 bn grew 8.2% qoq; largely helped by margin expansion in urea division. PAT, however degrew 12% qoq to Rs 961 mn; largely led by halving of other income and higher interest and depreciation charge.

Trading surprises, Textile holds up too: Trading revenues topped estimates and Ebit doubled on yoy/qoq basis to Rs 838 mn (highest trading EBIT ever). Adj for profits on selling a scrapped ship, we work the Shipping division losses to have increased marginally qoq. Fall in freight rates, higher bunker costs could have pulled down shipping division performance. Textile division that was weighed down by volatile cotton prices and huge inventory losses in FY12 reported marginal profits of Rs 53 mn (Rs 12 mn in Q1FY13). Like other fert companies, CHMB's working capital cycle has lengthened as well. Inventory/debtors have risen to 107/162 days compared to 33/114 days respectively; however this is expected to ease in the coming quarters.

Valuations attractive; Reiterate Buy: FY13E earnings driver could be firming urea prices (implies max realizations of US$400/mt) and profits from technology division, the two also to be helped by further INR weakening. Given poor offtake, likely erratic monsoon and excess channel inventory, we viewed opportunity to trade in fertilizers in FY13E to be limited; however the trading EBIT has increased by 71% to Rs 2 bn in 9MFY13. Marginal improvement in performance of shipping, technology and IMACID to support earnings in FY14E; should urea International prices come off too. While we model flat earnings during FY13-15E; we argue levers exists in terms of higher urea prices, sooner than expected revival of software business, weak INR and policy support to help earnings surprise on the upside. We maintain reforms in Urea are a compulsion than a choice. Valuations attractive (7.9x FY13E PER; 1.4x PBR and 5.3x EV/Ebitda); offers dividend yield of 3.0%; positive policy pronouncements in urea to augment earnings and stock performance over medium term. Reiterate Buy with a revised PT of Rs 85 (Earlier Rs 90).


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views on LIC Housing Finance Limited 4QFY2017 Results: Angel Broking
Wipro - Q4FY17 Result Review - Kotak Securities Limited
Views on Wipro Limited 4QFY2017 Results: Angel Broking
Axis Bank - Q4FY17 - Worst for the bank could get over in near term, better days ahead: Angel Broking
Ultratech Cement - Q4FY17 Result Review - Kotak Securities Limited
HDFC Bank back on growth trajectory: Angel Broking
Sun Pharmaceutical US Update: Angel Broking
Global ambiguity sizzles; Base metals' rally fizzles: Angel Broking
Asset quality a negative surprise form Yes Bank: Angel Broking
Heavy weight banks look a good bet: Angel Broking
Banks: Tightening the screws - Kotak
Utilities: The supply glut - Kotak
Insurance: Ending a strong year on a stronger note - Kotak
TCS - Q4FY17 result review - Kotak
Views on Tata Consultancy Services Limited 4QFY2017 Results: Angel Broking
Strategy: Small need not be beautiful - Kotak
Indiabulls Real Estate restructures to create value: Angel Broking
Infosys Q4 2017 results - Dipen Shah, Sr. Vice President - PCG Research, Kotak Securities Limited
Views on Infosys Ltd 4QFY2017 Results: Angel Broking
Infosys - 4QFY2017 Result Preview: Angel Broking
Metals & Mining (Attractive): 4QFY17 preview-when it shines the most - Kotak
Energy: Weaker end to a subdued year - Kotak
Apex court disallows rise in imported coal tariff, though awards compensation for lack of domestic coal
Utilities: Supreme Court-denies compensation, but with a rider - Kotak
Strategy: The curious case of the Indian market - Kotak Institutional Equities
Economy: INR: Appreciate, for now, but be cautious - Kotak Institutional Equities
Energy: OMCs Refining - marketing - Kotak Institutional Equities
Cement: Earnings weakness persists - Kotak Institutional Equities
Fall in IT conglomerates evened out by Banking counters: Angel Broking
Shankara Building Products lists at a healthy premium to issue price: Angel Broking
USFDA action on Indoco Plants: Angel Broking
Karur Vysya Bank - Easing troubles to pave way for growth: Angel Broking
Navin Fluorine International - The unique chemistry of growth: Angel Broking
Dr Reddy's inks distribution pact with Integra Life Sciences: Angel Broking
BS-IV rollout expected be neutral on the automobile sector: Angel Broking
Shankara Building Products Ltd - IPO Note - Sushil Finance
'R' for RERA - for Realty coming to Reality soon: Angel Broking
Reliance Capital - Refurbishing core; monetisation crucial; company update; Buy - Edelweiss
D-Mart delights its investors: Angel Broking
Shankara Building Products Limited - Thrust on retail to boost potential: Angel Broking
Impact of Rupee Strength on IT and Pharma: Angel Broking
Idea Surges 12% on the back of positive news flows: Angel Broking
Sun Pharmaceutical - USFDA to Lift Import Alert Regulator to permit supply of products from Mohali: Angel Broking
IT Update - Ban on premium processing of H1-B visas: Angel Broking
Tech Mahindra - Acquires CJS Solutions in US: Angel Broking
Dr. Reddy's Laboratories - Gets USFDA observation for Duvvada oncology formulation Facility: Angel Broking
VIP Industries - Travelling smart on the luggage track: Angel Broking
Avenue Supermarts - IPO Note - Numero Uno! - Reliance Securities
IT Update: Ban on premium processing of H1-B visas: Angel Broking
DATA WARS BEGIN... AND THE WINNER IS: THE DATA CONSUMER: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017